profit from every $100 of sales.
$0$100
Vanda Pharmaceuticals
$4.15+1.72% today
-5.3% in 1 year
1-year low $3.591-year high $9.56
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Vanda Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from $254 million in 2022 to $216 million in 2025, with -$220 million of profit last year.
SalesProfit
Vanda Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Vanda Pharmaceuticals | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Vanda Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 254 | 193 | 199 | 216 | |
| 230 | 178 | 187 | 203 | |
| 6 | -14 | -41 | -151 | |
| 9 | -10 | -31 | -139 | |
| 6 | 3 | -19 | -220 | |
| 0.11 | 0.04 | -0.33 | -3.74 | |
| 90.5% | 92.3% | 94.3% | 94.0% | |
| 2.5% | -7.2% | -20.5% | -70.0% | |
| 2.5% | 1.3% | -9.5% | -102.0% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 634 | 648 | 656 | 489 |
| Cash | 135 | 136 | 102 | 85 |
| Total debt | 11 | 9 | 12 | 13 |
| Total liabilities | 107 | 104 | 118 | 162 |
| 527 | 545 | 539 | 327 | |
| 57 | 58 | 58 | 59 | |
| 0.9% | -2.0% | -5.8% | -35.1% | |
| 1.2% | 0.5% | -3.5% | -67.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 32 | 13 | -16 | -109 | |
| 1 | 0 | 0 | 1 | |
| 31 | 12 | -16 | -110 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 16 | 14 | 12 | 9 |
Valuation
- –
- –
- –
- 1.4×
- 1.2×
- –
- –
- -44.0%
- -87.9%
- 0.0%
Profitability
- 94.0%
- -70.0%
- -102.0%
- -65.8%
- -52.8%
- -12.1%
- -61.4%
- -55.3%
- -53.8%
- 46.8%
Growth
- −5.3%
- –
- −579.8%
- –
- +1.5%
Financial health
- -0.5×
- 0.05
- 3.0%
- –
- 2.16
- 2.15
- 0.50
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 6%of 958
Bottom 5%of 888
Bottom 10%of 889
Bottom 1%of 987
What analysts expect
- Average price target
- $14.17
- Range
- $7.50 – $24.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | -0.82 | -0.53 | −54.7% |
| Feb 11, 2026 | -0.46 | -2.18 | +78.9% |
| Oct 29, 2025 | -0.38 | -0.31 | −22.6% |
| Jul 31, 2025 | -0.46 | -0.34 | −35.3% |
| May 7, 2025 | -0.50 | -0.55 | +9.1% |
| Feb 13, 2025 | -0.08 | -0.14 | +42.9% |
| Nov 6, 2024 | -0.09 | -0.17 | +47.1% |
| Jul 31, 2024 | -0.08 | -0.21 | +61.9% |
News
Why Are Nasdaq Futures Rising Premarket? MU, TSLA, CAPR, VNDA, ASTS, HOOD, BA Stocks In FocusYahoo Finance · Sep 30, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
33No pass
Benjamin Graham
57No pass
Philip Fisher
44No pass
Peter Lynch
30No pass
Joel Greenblatt
2No pass
Charlie Munger
37No pass
Terry Smith
28No pass
Questions about Vanda Pharmaceuticals
Is Vanda Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Vanda Pharmaceuticals AI analysis
What does Vanda Pharmaceuticals do?
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. It is in Biotechnology.
Does Vanda Pharmaceuticals pay a dividend?
No. Vanda Pharmaceuticals does not pay a dividend at the moment.
Is Vanda Pharmaceuticals stock halal?
No. Vanda Pharmaceuticals does not pass our halal screen: its cash and confirmed interest-bearing investments are 34% of its market value, at or above the 33% limit. How we check
How has Vanda Pharmaceuticals stock done over the past year?
Down 5.3% over the past twelve months, to $4.15. It traded between $3.59 and $9.56 and is 56.6% below its high.
Who are Vanda Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Vanda Pharmaceuticals's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.